2022
Continuous Glucose Monitoring in Adults With Type 1 Diabetes With 35 Years Duration From the DCCT/EDIC Study.
Gubitosi-Klug RA, Braffett BH, Bebu I, Johnson ML, Farrell K, Kenny D, Trapani VR, Meadema-Mayer L, Soliman EZ, Pop-Busui R, Lachin JM, Bergenstal RM, Tamborlane WV. Continuous Glucose Monitoring in Adults With Type 1 Diabetes With 35 Years Duration From the DCCT/EDIC Study. Diabetes Care 2022, 45: 659-665. PMID: 35076697, PMCID: PMC8918229, DOI: 10.2337/dc21-0629.Peer-Reviewed Original ResearchConceptsType 1 diabetesContinuous glucose monitoringInsulin pumpDCCT/EDIC studyComplications Trial/EpidemiologyGlucose monitoringPercent timeRelevant clinical goalsYears of ageMean sensor glucoseSubset of adultsComplications StudyEDIC studyEntire recording periodOlder patientsGlycemic excursionsDiabetes controlSignificant hypoglycemiaDiabetes InterventionsYears durationHypoglycemiaSensor glucoseClinical goalsHyperglycemic excursionsType 1
2020
Effect of Exercise and Meals on Continuous Glucose Monitor Data in Healthy Individuals Without Diabetes
DuBose SN, Li Z, Sherr JL, Beck RW, Tamborlane WV, Shah VN. Effect of Exercise and Meals on Continuous Glucose Monitor Data in Healthy Individuals Without Diabetes. Journal Of Diabetes Science And Technology 2020, 15: 593-599. PMID: 32064911, PMCID: PMC8120054, DOI: 10.1177/1932296820905904.Peer-Reviewed Original ResearchConceptsEffects of exerciseSensor glucose levelsHealthy individualsResistance exerciseNadir glucoseGlucose levelsNonobese body mass indexT1D Exchange Clinic NetworkPeak postprandial glucoseBody mass indexGlucose concentrationTime of mealsNadir glucose concentrationsConsumption of alcoholMass indexPostprandial glucoseNonexercise dayAerobic exerciseExercise dayClinic networkMean changeFuture therapiesDiabetesDexcom G6Glucose monitor data
2019
Biologic and social factors predict incident kidney disease in type 1 diabetes: Results from the T1D exchange clinic network
McGill JB, Wu M, Pop-Busui R, Mizokami-Stout K, Tamborlane WV, Aleppo G, Gubitosi-Klug RA, Haller MJ, Willi SM, Foster NC, Zimmerman C, Libman I, Polsky S, Rickels MR. Biologic and social factors predict incident kidney disease in type 1 diabetes: Results from the T1D exchange clinic network. Journal Of Diabetes And Its Complications 2019, 33: 107400. PMID: 31279735, DOI: 10.1016/j.jdiacomp.2019.06.005.Peer-Reviewed Original ResearchConceptsAdverse kidney outcomesDiabetic kidney diseaseKidney outcomesType 1 diabetesKidney diseaseRisk factorsRisk of DKDDevelopment of DKDT1D Exchange Clinic NetworkAlbumin/creatinine ratioIncident kidney diseaseBlood pressure controlModifiable risk factorsT1D Exchange RegistryUrine albumin measurementsLow education levelModern clinical practiceEGFR declineIncident albuminuriaT1D durationBaseline characteristicsSerum creatinineCreatinine ratioMajor complicationsHigher HbA1cContinuous Glucose Monitoring Profiles in Healthy Nondiabetic Participants: A Multicenter Prospective Study
Shah VN, DuBose SN, Li Z, Beck RW, Peters AL, Weinstock RS, Kruger D, Tansey M, Sparling D, Woerner S, Vendrame F, Bergenstal R, Tamborlane WV, Watson SE, Sherr J. Continuous Glucose Monitoring Profiles in Healthy Nondiabetic Participants: A Multicenter Prospective Study. The Journal Of Clinical Endocrinology & Metabolism 2019, 104: 4356-4364. PMID: 31127824, PMCID: PMC7296129, DOI: 10.1210/jc.2018-02763.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoringMedian timeAge groupsProspective studyNondiabetic individualsGlucose levelsAverage glucoseNonobese body mass indexT1D Exchange Clinic NetworkContinuous glucose monitoring (CGM) profilesInsulin-requiring patientsMulticenter prospective studyBody mass indexDifferent age groupsNondiabetic childrenNondiabetic populationGlycemic profileMass indexNondiabetic participantsGlycemic variabilityMean glucoseClinic networkCGM metricsGlycemic metricsGlucose monitoringState of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA, Maahs DM, Tamborlane WV, Bergenstal R, Smith E, Olson BA, Garg SK. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018. Diabetes Technology & Therapeutics 2019, 21: 66-72. PMID: 30657336, PMCID: PMC7061293, DOI: 10.1089/dia.2018.0384.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoringT1D Exchange RegistryRegistry participantsDiabetes managementHigher mean HbA1cType 1 diabetesType 1 diabetes managementMinority of adultsProfile of adultsHbA1c goalDiabetic ketoacidosisMean HbA1cSevere hypoglycemiaClinical outcomesT1D ExchangeT1D managementAge 30Longitudinal changesADA goalsAge 28Age 15Glucose monitoringYoung adultsCGM usersRacial differences
2017
Postprandial Dosing of Bolus Insulin in Patients with type 1 Diabetes: a Cross-sectional Study Using Data From the T1d Exchange Registry
Peters A, Van Name MA, Thorsted B, Piltoft JS, Tamborlane WV. Postprandial Dosing of Bolus Insulin in Patients with type 1 Diabetes: a Cross-sectional Study Using Data From the T1d Exchange Registry. Endocrine Practice 2017, 23: 1201-1209. PMID: 28704103, DOI: 10.4158/ep171813.or.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBlood GlucoseBlood Glucose Self-MonitoringChildChild, PreschoolCross-Sectional StudiesDiabetes Mellitus, Type 1Diabetic KetoacidosisDrug Dosage CalculationsFemaleHumansHypoglycemiaInfantInsulinInsulin Infusion SystemsMaleMiddle AgedPostprandial PeriodRegistriesYoung AdultConceptsRapid-acting insulin analoguesLarger insulin doseT1D Exchange RegistryType 1 diabetesCross-sectional studyDiabetic ketoacidosisInsulin doseGreater prevalenceCurrent rapid-acting insulin analoguesInsulin analoguesSelf-monitoring blood glucosePercent of patientsCharacteristics of patientsPoor glycemic controlExclusion of patientsBody mass indexContinuous glucose monitoringPostprandial dosingGlycemic controlSevere hypoglycemiaBolus insulinMass indexEnrollment questionnaireBlood glucoseGlucose levelsGlucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes
Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS, Brazg RL, Ilany J, Slover RH, Anderson SM, Bergenstal RM, Grosman B, Roy A, Cordero TL, Shin J, Lee SW, Kaufman FR. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics 2017, 19: 155-163. PMID: 28134564, PMCID: PMC5359676, DOI: 10.1089/dia.2016.0421.Peer-Reviewed Original ResearchConceptsHybrid closed-loop insulin delivery systemGlucose valuesDiabetic ketoacidosis eventsMulticenter pivotal trialStudy phaseBlood sample testingType 1 diabetesClosed-loop insulin delivery systemBlood glucose valuesHome useContinuous glucose monitoringSensor glucose valuesHCl therapyKetoacidosis eventsHybrid closed-loop systemPivotal trialsInsulin delivery systemsGlucose outcomesMedtronic MiniMedType 1Glucose monitoringInsulin deliveryAdultsStayAdolescents
2016
Effective Translation of an Intensive Lifestyle Intervention for Hispanic Women With Prediabetes in a Community Health Center Setting
Van Name MA, Camp AW, Magenheimer EA, Li F, Dziura JD, Montosa A, Patel A, Tamborlane WV. Effective Translation of an Intensive Lifestyle Intervention for Hispanic Women With Prediabetes in a Community Health Center Setting. Diabetes Care 2016, 39: 525-531. PMID: 26908915, PMCID: PMC4806769, DOI: 10.2337/dc15-1899.Peer-Reviewed Original ResearchMeSH KeywordsAdiposityAdolescentAdultAgedBody Mass IndexChoice BehaviorCommunity Health CentersDiabetes Mellitus, Type 2ExerciseFeasibility StudiesFemaleFood PreferencesHispanic or LatinoHumansInsulinLife StyleMiddle AgedPilot ProjectsPrediabetic StateRisk FactorsSocioeconomic FactorsWaist CircumferenceWeight LossYoung AdultConceptsIntensive lifestyle interventionDiabetes Prevention ProgramCommunity health center settingUsual care groupType 2 diabetesHealth center settingHispanic womenILI groupLifestyle interventionCare groupOral glucose tolerance testCenter settingLow-income Hispanic womenWeight lossSimilar baseline weightGlucose tolerance testPercent body fatType of interventionCHC settingsDPP interventionsUsual careBaseline weightWaist circumferenceGlucose excursionsTolerance test
2015
Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry
Miller KM, Foster NC, Beck RW, Bergenstal RM, DuBose SN, DiMeglio LA, Maahs DM, Tamborlane WV. Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry. Diabetes Care 2015, 38: 971-978. PMID: 25998289, DOI: 10.2337/dc15-0078.Peer-Reviewed Original ResearchConceptsYears of ageType 1 diabetesT1D Exchange Clinic RegistryContinuous glucose monitoringDiabetic ketoacidosisSevere hypoglycemiaClinic registryMetabolic controlOutcome of treatmentOptimal metabolic controlRegistry findingsAdvanced diabetes technologiesAverage HbA1cMean hemoglobinYounger patientsCommon complicationCurrent treatmentNew therapiesAge 30HbA1cType 1DiabetesGlucose monitoringDiabetes technologyAgeImproved Postprandial Glucose Control Using the InsuPad Device in Insulin-Treated Type 2 Diabetes
Raz I, Bitton G, Feldman D, Alon T, Pfutzner A, Tamborlane WV. Improved Postprandial Glucose Control Using the InsuPad Device in Insulin-Treated Type 2 Diabetes. Journal Of Diabetes Science And Technology 2015, 9: 639-643. PMID: 25883166, PMCID: PMC4604546, DOI: 10.1177/1932296815578881.Peer-Reviewed Original ResearchConceptsRapid-acting insulin analoguesType 2 diabetesMeal tolerance testPlasma insulin levelsInsulin analoguesInsulin levelsGlucose excursionsInjection siteInsulin absorptionType 2 diabetic patientsPostmeal glucose excursionsStandardized liquid mealPostprandial glucose excursionsTime-action profilePostprandial glucose controlInsulin therapyDiabetic patientsGlucose controlLiquid mealOvernight fastInsulin aspartTolerance testPostprandial hyperglycemiaPremeal bolusesPremeal injections
2013
Challenges and Future Directions of the T1D Exchange Clinic Network and Registry
Miller KM, Xing D, Tamborlane WV, Bergenstal RM, Beck RW. Challenges and Future Directions of the T1D Exchange Clinic Network and Registry. Journal Of Diabetes Science And Technology 2013, 7: 963-969. PMID: 23911177, PMCID: PMC3879760, DOI: 10.1177/193229681300700418.Peer-Reviewed Original ResearchConceptsT1D Exchange Clinic NetworkClinic registryClinic networkT1D Exchange Clinic RegistryType 1 diabetes mellitusPublic health issueElectronic health recordsDiabetes historyDiabetes mellitusDiabetes CenterMedical recordsInsulin administrationMedical conditionsWide age rangeWeb-based questionnaireRegistryAutoimmune T1DMHealth issuesHealth recordsAge rangeData extractionParticipant completionT1DMClinicLaboratory results
2012
The T1D Exchange Clinic Registry
Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA, Network F. The T1D Exchange Clinic Registry. The Journal Of Clinical Endocrinology & Metabolism 2012, 97: 4383-4389. PMID: 22996145, DOI: 10.1210/jc.2012-1561.Peer-Reviewed Original ResearchConceptsT1D Exchange Clinic RegistryClinic registryAutoimmune type 1 diabetesFirst-degree family membersClinic-based registrySevere hypoglycemic eventsChronic diabetic complicationsType 1 diabetesContinuous glucose monitoringAssessment of associationsDiabetes historyDiabetic ketoacidosisEndocrinology centersPatient characteristicsRenal diseaseChart extractionT1D ExchangeGlycosylated hemoglobinHypoglycemic eventsDiabetic complicationsRetinopathy treatmentGeneral healthFamily historyMedical conditionsRegistry
2011
Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study Results from the 6-month continuation phase
Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Perkins BA, Welsh JB, Willi SM, Wood MA, . Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study Results from the 6-month continuation phase. Diabetes Care 2011, 34: 2403-2405. PMID: 21933908, PMCID: PMC3198292, DOI: 10.2337/dc11-1248.Peer-Reviewed Original ResearchOptimal Sampling Intervals to Assess Long-Term Glycemic Control Using Continuous Glucose Monitoring
Xing D, Kollman C, Beck RW, Tamborlane WV, Laffel L, Buckingham BA, Wilson DM, Weinzimer S, Fiallo-Scharer R, Group K. Optimal Sampling Intervals to Assess Long-Term Glycemic Control Using Continuous Glucose Monitoring. Diabetes Technology & Therapeutics 2011, 13: 351-358. PMID: 21299401, PMCID: PMC6468940, DOI: 10.1089/dia.2010.0156.Peer-Reviewed Original Research
2010
STAR 3 Randomized Controlled Trial to Compare Sensor-Augmented Insulin Pump Therapy with Multiple Daily Injections in the Treatment of Type 1 Diabetes: Research Design, Methods, and Baseline Characteristics of Enrolled Subjects
Davis SN, Horton ES, Battelino T, Rubin RR, Schulman KA, Tamborlane WV. STAR 3 Randomized Controlled Trial to Compare Sensor-Augmented Insulin Pump Therapy with Multiple Daily Injections in the Treatment of Type 1 Diabetes: Research Design, Methods, and Baseline Characteristics of Enrolled Subjects. Diabetes Technology & Therapeutics 2010, 12: 249-255. PMID: 20210562, PMCID: PMC2883476, DOI: 10.1089/dia.2009.0145.Peer-Reviewed Original ResearchConceptsMultiple daily injectionsContinuous subcutaneous insulin infusionType 1 diabetesPercentage of subjectsPump therapyEnd pointBaseline characteristicsDaily injectionsKey safety end pointsType 1Sensor-Augmented Pump TherapyReal-time continuous glucose monitoringSensor-Augmented Insulin Pump TherapyNormal glycemic rangeTertiary end pointPrimary end pointSafety end pointSecondary end pointsInsulin pump therapySubcutaneous insulin infusionYears of treatmentContinuous glucose monitoringMDI cohortSevere hypoglycemiaClinical outcomes
2005
Disease Management in the Young Diabetic Patient: Glucose Monitoring, Coping Skills, and Treatment Strategies
Weinzimer SA, Doyle EA, Tamborlane WV. Disease Management in the Young Diabetic Patient: Glucose Monitoring, Coping Skills, and Treatment Strategies. Clinical Pediatrics 2005, 44: 393-403. PMID: 15965545, DOI: 10.1177/000992280504400503.Peer-Reviewed Original ResearchMeSH KeywordsAdaptation, PsychologicalAdolescentAdolescent BehaviorAdultAge FactorsAgedAttitude to HealthBlood GlucoseBlood Glucose Self-MonitoringChildDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2FemaleHumansHypoglycemic AgentsInjections, SubcutaneousInsulinInsulin ResistanceMaleMiddle AgedPatient CompliancePatient Education as TopicPrognosisRisk AssessmentSeverity of Illness IndexTreatment OutcomeConceptsYoung diabetic patientsGlycemic controlDiabetic patientsType 1 diabetes mellitusContinuous subcutaneous insulin infusionPresence of hypoglycemiaSubcutaneous insulin infusionType 2 diabetesDisease managementContinuous glucose-monitoring systemPositive treatment outcomesGlucose-monitoring systemInsulin glargineYounger patientsDiabetes mellitusHypoglycemic episodesJuvenile patientsNocturnal hypoglycemiaInsulin infusionTreatment outcomesTreatment strategiesCareful monitoringDiabetesPatientsGlucose monitoring
1994
Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults.
Boulware SD, Tamborlane WV, Rennert NJ, Gesundheit N, Sherwin RS. Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults. Journal Of Clinical Investigation 1994, 93: 1131-1139. PMID: 8132753, PMCID: PMC294058, DOI: 10.1172/jci117065.Peer-Reviewed Original ResearchConceptsRecombinant human insulin-like growth factorInsulin-like growth factorHuman insulin-like growth factorMiddle-aged subjectsC-peptideYoung subjectsBasal IGF-I levelsHealthy middle-aged subjectsGlucose uptakeGrowth factorAdverse metabolic changesFree fatty acid levelsIGF-I levelsRelative insulin deficiencyEuglycemic clamp studiesFat oxidation rateDose-response relationshipFatty acid levelsInsulin-induced stimulationMiddle-aged adultsBasal insulinInsulin deficiencyMetabolic effectsClamp studiesRhIGF